Pfizer Announces Top-Line Results From Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine
March 19, 2020
March 19, 2020
NEW YORK, March 19 -- Pfizer, a pharmaceutical company, issued the following news release:
Pfizer Inc. (NYSE:PFE) announced top-line results from one of its Phase 3 studies (NCT03760146), which evaluated the safety and immunogenicity of its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate in adults 18 years of age or older not previously vaccinated against pneumococcal disease. The primary immunogenicity objectives of non-inferiority for the 20 serotypes included in 20vPn . . .
Pfizer Inc. (NYSE:PFE) announced top-line results from one of its Phase 3 studies (NCT03760146), which evaluated the safety and immunogenicity of its 20-valent pneumococcal conjugate vaccine (20vPnC) candidate in adults 18 years of age or older not previously vaccinated against pneumococcal disease. The primary immunogenicity objectives of non-inferiority for the 20 serotypes included in 20vPn . . .